Overview of Cartan

Quick Facts

Property	Description
Active ingredient	Losartan potassium
Form	Oral film-coated tablet
Pharmacological class	Angiotensin II Receptor Blocker (ARB)
Common use	Antihypertensive agent (blood pressure management)
Origin	Synthetic compound

What Type of Medicine is Cartan (Losartan)?

Cartan is the trade name for the drug Losartan, a synthetic, prescription medicine officially classified as an Angiotensin II Receptor Blocker (ARB). It is essentially an antihypertensive agent, which means its primary purpose is to help manage high blood pressure. Losartan’s identity is defined by its role in modulating the Renin-Angiotensin-Aldosterone System (RAAS), a crucial hormonal pathway that regulates blood vessel tone and fluid balance. Its established use in circulatory management is confirmed by its inclusion on the World Health Organization's List of Essential Medicines.

Composition and General Purpose of Losartan Potassium

The sole active ingredient in Cartan is Losartan potassium, which is administered as an oral film-coated tablet. This chemical compound is specifically designed to act as a selective AT1 receptor antagonist. Its general benefit stems from its core function: the Losartan molecule promotes vasodilation (widening of blood vessels) throughout the body. By reducing the overall resistance within the circulatory system, the medicine achieves its general purpose of lowering systemic blood pressure, easing the burden on the cardiovascular system.

How Does Losartan Differ from Other Blood Pressure Medicines?

Losartan's mechanism, AT1 receptor blockade, is a targeted approach that directly prevents the powerful vasoconstrictor Angiotensin II from binding to its receptors in blood vessel walls. This targeted action is a key differentiating factor from older treatments, such as Angiotensin-Converting Enzyme (ACE) inhibitors, which work earlier in the cascade by blocking the enzyme that produces Angiotensin II. As a single-ingredient product, Losartan offers a focused intervention for individuals requiring systemic blood pressure management.

Regulatory References

Losartan - WHO Essential Medicines List

What side effects are possible with Cartan?

Possible Side Effects and Safety Information

The officially documented adverse effects for Cartan (Losartan potassium) are organized by frequency and the body system affected, according to government regulatory standards such as those from the FDA and the EMA.

Adverse Reactions and Classification

Classification	Examples of Documented Adverse Reactions (by System)
Common (1% to 10%)	Dizziness, upper respiratory infection, nasal congestion, back pain, headache, and vertigo.
Uncommon (< 1%)	Palpitations, somnolence, sleep disorders, abdominal pain, nausea, vomiting, pruritus, rash, and oedema.
Rare (< 0.1%)	Angioedema (swelling of the face, lips, throat), hepatitis, vasculitis, and rhabdomyolysis.

Adverse effects are documented across multiple System-Organ Classes, including the Nervous System (e.g., dizziness), Gastrointestinal Disorders (e.g., constipation), and Musculoskeletal System (e.g., back pain).

Serious Safety Considerations

Serious Adverse Reactions officially noted in regulatory documents include the rare but severe risk of Angioedema and the potential for Renal Function Deterioration, which may be reversible upon discontinuation. Losartan can also lead to electrolyte imbalances such as Hyperkalaemia (elevated potassium levels), which requires careful monitoring.

Time- or Exposure-Related Patterns

Symptomatic hypotension (a drop in blood pressure with symptoms) may occur, particularly after the first dose or following an increase in dosage.

Population-Specific Safety Constraints

The official labeling contains specific constraints for certain patient groups:

Pregnancy: Use during the second and third trimesters is strictly contraindicated due to documented fetal toxicity. Use in the first trimester is not recommended.
Severe Hepatic Impairment: The medicine is contraindicated in patients with severe liver dysfunction.
Dual RAAS Blockade: Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes or moderate-to-severe renal impairment.

This regulatory structure defines the official safety profile, distinguishing between frequently observed effects and rare, yet critical, safety concerns.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cartan (Losartan) overdose is defined by its core effect on blood pressure and mandated emergency actions. The principal documented manifestation of overdose is hypotension (excessively low blood pressure).

Other documented overdose presentations may include a disturbed heart rate, specifically tachycardia (rapid heartbeat) or, less commonly, bradycardia (slow heartbeat). Severe outcomes can include profound hypotension leading to shock, as well as the potential for hyperkalemia and acute deterioration of renal function.

Classification	Official Regulatory Statement
Severity classification	Capable of causing severe manifestations, including shock and acute renal failure.
Overdose-context constraints	No specific antidote is known. Hemodialysis is ineffective for drug removal.

Individuals with suspected overdosage must seek immediate medical attention. If severe symptoms are present, such as collapse, difficulty breathing, or inability to be awakened, emergency services must be contacted immediately. Management is primarily symptomatic and supportive treatment, including volume correction for hypotension. A specific risk of hypoglycemia in pediatric patients following overdose is also noted in regulatory guidance.

This structure defines the necessary emergency response based on the drug's core risks and the known limits of intervention, strictly as stated in government-authorized prescribing information.

Therapeutic Uses of Cartan

Quick Facts: Uses of Cartan

Therapeutic Domain	Primary Use
Cardiovascular	Management of high blood pressure (hypertension)
Cardiovascular	Support in the management of heart rhythm disorders (arrhythmias)
Cardiovascular	Helps relieve symptoms of angina (heart-related chest discomfort)
Post-Heart Event	Used as a component of treatment following a heart attack (myocardial infarction)

Cartan is a medication prescribed to support cardiovascular health. Its primary therapeutic domains include assisting in the management of elevated blood pressure, a key measure to reduce the risk of serious cardiovascular events. It is also used to help manage specific heart rhythm irregularities.

Furthermore, Cartan is indicated as a treatment option to relieve symptoms associated with angina pectoris, which is heart-related chest discomfort. This medication is additionally utilized in an early treatment capacity following a heart attack to help manage the condition. The use of Cartan may support the body in maintaining blood pressure within an acceptable range and contribute to a comprehensive care strategy for heart-related concerns. Patients should consult their specialist to review all approved therapeutic uses and relevant information.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cartan?

The population eligibility for Cartan (Losartan) is strictly defined by regulatory documents, distinguishing between absolute exclusions and restricted use conditions.

Absolute Contraindications

Cartan is contraindicated and must not be used in the following populations:

Patients with known hypersensitivity to Losartan or any component of the medicine.
Women in the second or third trimesters of pregnancy.
Patients with severe hepatic impairment.
Patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2) who are simultaneously receiving Aliskiren.

Restricted and Age-Based Eligibility

Population Group	Regulatory Status
Children under 6 years	Not recommended; safety and efficacy are not established.
Pediatric patients (6–18 years)	Allowed only for hypertension, provided renal function (GFR) is adequate (ge 30 mL/min/1.73 m^2).
Mild-to-moderate Hepatic Impairment	Requires use to be initiated at a lower starting dose.
Pregnancy (First Trimester)	Not recommended; use should be discontinued as soon as pregnancy is detected.
Breastfeeding	Not recommended, especially when nursing a newborn or preterm infant.

The regulatory profile clearly establishes the groups permitted to use the medicine (Adults, and children ge 6 for hypertension) and those who are formally excluded due to pregnancy status or specific comorbid conditions.

What should I know about interactions with other medicines?

Cartan Interactions with Other Medicines and Products

This section summarizes officially documented interaction patterns for Cartan (Losartan potassium) found in government regulatory prescribing information.

Documented High-Risk Combinations

Aliskiren: The co-administration of Cartan with Aliskiren is formally contraindicated in patients diagnosed with diabetes mellitus or those with renal impairment (GFR <60 mL/min/1.73 m^2).

Interaction Categories

Interaction Type	Interacting Substances/Class	Official Interaction Finding
Potassium & Electrolytes	Potassium supplements, Potassium-sparing diuretics	Increased risk of hyperkalemia (elevated serum potassium levels).
Pharmacodynamic	NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)	May cause a diminished antihypertensive effect and risk of renal function change.
Clearance Modification	Lithium	Can cause a documented increase in serum lithium concentrations and potential toxicity.
Metabolic (CYP)	Fluconazole, Rifampin	Alters exposure by modifying the AUC/Cmax of Losartan and its active metabolite (E-3174).

Other Population and Product Notes

Official labeling indicates that hepatic impairment is associated with reduced clearance and increased exposure to Losartan. Additionally, the co-administration of Cartan with food slows its absorption, resulting in a decreased peak concentration (C max).

Mechanism of Action

Cartan is a human monoclonal antibody ( IgG2) engineered to target and bind with high affinity to the receptor activator of nuclear factor kappa-B ligand (RANKL). RANKL is a transmembrane or soluble protein that functions as the primary effector of osteoclast formation, activity, and survival. Cartan acts as a specific inhibitor, preventing the binding of RANKL to its cognate receptor, RANK (receptor activator of NF-kappa B), which is expressed on the surface of pre-osteoclasts and mature osteoclasts. This blockade interrupts the intracellular signaling pathway required for osteoclast differentiation.

The inhibition of the RANKL-RANK interaction effectively suppresses osteoclastogenesis (the development of osteoclasts) and significantly decreases the overall bone-resorbing activity of mature osteoclasts. By neutralizing RANKL, the molecular signal that drives bone breakdown is removed. This mechanistic cascade leads to a reduction in the rate of bone resorption, thereby modulating the balance of bone remodeling.

Dosage and Administration Information

Official Administration Guidelines

Cartan (Losartan) is administered orally as a film-coated tablet or as an extemporaneously prepared oral suspension. The proper use of this medicine is structured around a once-daily dosing schedule, which should be maintained at about the same time every day for consistency. The tablets may be administered with or without food, and the official instruction is to swallow the tablet whole with a glass of water.

Standard Labeled Dosing

The usual adult starting dose for most indications, including hypertension, is 50 mg once daily. The dosage can be increased up to a maximum of 100 mg once daily. For adults with possible intravascular volume depletion or mild-to-moderate hepatic impairment, a lower initial dose of 25 mg once daily is recommended based on pharmacokinetic data showing potentially higher drug concentrations. The maximum effect is typically attained after three to six weeks of therapy, which informs the timing for any dose adjustments.

Special Administration Rules

Instruction	Detail
Pediatric Use (Ages 6–16)	Initial dose is 0.7 mg/kg once daily (up to 50 mg total); not recommended for children under 6.
Missed Dose Rule	If a dose is missed, the patient should skip it and continue the regular dosing schedule. Do not double the dose to compensate.

These guidelines define the standardized use protocol, specifying the exact route, standard dose ranges, and necessary adjustments for predictable use.

Recent Clinical Evidence

Research evidence / Overview of studies for Cartan

The available information on Cartan (Losartan) is based on official clinical trials, including numerous randomized controlled trials (RCTs) and long-term studies, which focused on research exploring several cardiovascular and renal conditions. This overview focuses only on the type of evidence available and what the studies explored, without offering clinical guidance or making claims about personal outcomes.

Research Exploring High Blood Pressure

Studies related to hypertension include many RCTs that compared Losartan to either a placebo or to other active treatments. These research efforts typically monitored outcomes related to systolic and diastolic blood pressure levels. Long-term trials also examined major secondary outcomes such as the occurrence of cardiovascular events (like heart attack and stroke) in the observed patient groups.

Regulatory analyses reported measurements of shifts in both systolic and diastolic blood pressure levels. One major long-term study reported on the incidence of a combined cardiovascular endpoint when comparing a Losartan-based regimen to an atenolol-based regimen. A key limitation is that the observed patterns for certain cardiovascular outcomes did not apply to the specific Black patient subgroup studied in the major long-term trial.

Research Exploring Diabetic Kidney Disease

Research for this use focused on patients with Type 2 Diabetes and high blood pressure who had elevated protein in the urine (proteinuria). Studies were typically large-scale, long-term randomized trials. The main study (RENAAL) examined a severe composite endpoint: the time until a patient required dialysis, experienced a doubling of serum creatinine levels, or death. Trials reported observations on the time it took for patients to reach this pre-defined major composite renal endpoint compared to the placebo group.

Evidence in Specific Patient Populations and Uncertainties

Studies have explored specific patient groups outside of the general adult population: Children and Adolescents (ages 6–16 years) were evaluated with research focusing on measuring blood pressure changes. Older Adults were also included in major trials. However, data for certain groups remain insufficient, particularly for patients with the most severe stage of heart failure (NYHA Class IV) and for those with severe co-existing kidney problems.

Key Studies & References

WHO Model List of Essential Medicines (Losartan listing)

Frequently Asked Questions (FAQ)

Common questions about Cartan (FAQ)

Q: Do I need to change my diet while taking Cartan?

Official product information notes interactions with potassium supplements and high levels of potassium in the diet, which is noted in the official information. Taking the medicine with food can slow its absorption, but regulatory documents state it may be taken with or without food.

Q: Is Cartan safe for long-term use?

Studies and official information indicate that the safety profile is based on clinical trials where patients were observed for several years for chronic conditions like hypertension. This reflects the evidence available for its use in long-term management.

Q: Is it common to feel tired after starting Cartan?

Tiredness or fatigue is not typically listed as a Common adverse reaction in official product information. However, related nervous system effects, such as dizziness, are frequently reported, and somnolence (sleepiness) is sometimes reported as an uncommon effect.

Q: Can Cartan interact with everyday supplements like vitamins?

Official regulatory information warns of a risk of elevated potassium levels (hyperkalemia) when the medicine is used with potassium-containing supplements or salt substitutes. Official information highlights the importance of discussing all supplements with a healthcare provider.

Q: Are there any specific foods or drinks to avoid while on Cartan?

Official labeling notes the need for caution regarding concurrent consumption of potassium-containing foods or salt substitutes. This caution is in place due to the risk of developing hyperkalemia (elevated serum potassium levels).

Q: Is Cartan the same class of drug as [Specific common drug name]?

Regulatory documents classify Cartan (Losartan) as an Angiotensin II Receptor Blocker (ARB). This classification means it works by targeting a specific receptor in the body’s blood pressure regulation system, making it distinct from other classes of blood pressure medicine, such as ACE inhibitors.

Q: What does 'contraindicated' mean in relation to Cartan?

In official drug documentation, a contraindication describes a specific medical condition or circumstance where the risk of using the medicine outweighs any possible benefit. When a drug is contraindicated, it is considered inappropriate for use in that specific circumstance.

Q: Are there any specific warnings for people with heart conditions who take Cartan?

Official warnings note that the medicine is not recommended for individuals with the most severe stage of heart failure (NYHA Class IV). The labeling also indicates an increased risk of symptomatic low blood pressure (hypotension) after the initial dose.

Q: Do I need a special prescription or monitoring to get Cartan?

Official management guidelines address the monitoring of blood tests for serum potassium and kidney function (creatinine), especially for at-risk patients. This is due to the drug’s effects on the body's fluid and electrolyte balance.

Q: What are the potential risks of taking Cartan with over-the-counter cold medicine?

Official drug-interaction documents state that using this medicine with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common in cold medicines, may diminish the blood pressure-lowering effect. There is also a potential risk of changes in kidney function associated with this combination.

Q: Is Cartan metabolized quickly by the body?

Official regulatory documents describe the medicine's time in the body using a measure called half-life. The main drug compound has a half-life of about 2 hours, while its active form, known as a metabolite, has a longer half-life ranging from 6 to 9 hours.

Q: Can Cartan be used for things other than its main approved use?

Regulatory documents explicitly list the only approved uses as the treatment of hypertension (high blood pressure) and diabetic nephropathy (kidney disease). Official information does not describe, support, or advise on any other uses.

Q: What happens if I stop taking Cartan suddenly?

Regulatory information does not typically require a dose reduction before discontinuation. Regulatory information indicates that the blood pressure-lowering effects will stop, and high blood pressure may return to the previous levels.

Q: Does Cartan affect how I feel emotionally?

Official documentation lists effects on the nervous system, such as dizziness and sleep disorders, but does not typically include specific psychiatric terms like changes in mood or anxiety levels among the commonly reported adverse reactions.

Q: Does Cartan cause weight gain or loss?

Official labeling does not typically list significant changes in body weight as a common adverse reaction. It may list uncommon effects related to metabolism or fluid balance, such as oedema (swelling due to fluid retention).

Q: How long can I expect to take Cartan?

The medicine is prescribed for conditions, like high blood pressure, that are generally managed as a chronic, long-term part of a treatment plan. The duration of therapy is determined by the treating clinician based on the individual condition.

Q: Do all patients get side effects from Cartan?

Adverse reactions in official documents are described using frequency percentages (e.g., Common: 1% to 10%), indicating that side effects are probabilistic. This means that they do not occur in every person taking the drug.

Q: Does Cartan have any known interactions with birth control pills?

Official regulatory interaction studies did not show a clinically significant effect on common hormonal contraceptives (such as ethinyl estradiol and levonorgestrel).

Q: Is it true that Cartan requires blood tests?

Official management guidelines address the monitoring of blood tests for serum potassium and kidney function (creatinine), especially in at-risk patients, due to the drug's effects on the body's fluid and electrolyte balance.

Q: Can I take Cartan if I am also taking medicine for allergies?

Official interaction warnings are focused on specific drug classes. The clinical relevance of interactions depends on the active ingredients of the allergy medicine; therefore, all concurrent medications must be reviewed by a healthcare provider.

Q: Is Cartan addictive or habit-forming?

Official labeling states that Cartan (Losartan) is not known to be associated with drug abuse or physical dependence.

Q: Does using Cartan mean I cannot drink any alcohol at all?

Regulatory information indicates that consuming alcohol while taking this medicine may increase the risk of experiencing low blood pressure (hypotension). This may lead to symptoms like dizziness.

Q: Can Cartan interact with herbal products like St. John's Wort?

Official labeling notes that caution is addressed regarding products that may affect liver enzymes, particularly CYP2C9, which is the enzyme system that metabolizes the medicine. Some herbal products, such as St. John's Wort, are known to affect these enzymes, potentially altering the medicine's exposure in the body.

Q: Can Cartan cause changes in mood or anxiety levels?

Regulatory documents list adverse effects on the nervous system (dizziness) and sleep disorders, but changes in mood or anxiety levels are not typically listed as common side effects.

Q: Does Cartan affect fertility in men or women?

Regulatory nonclinical studies, typically conducted in animals like rats to assess reproductive risk, reported no adverse effects on the fertility of male or female animals.

Q: What information is publicly available about the clinical trials for Cartan?

Official regulatory bodies base their approval on extensive clinical trial data. This data is often made available for public review in government-run databases, such as the NIH Clinical Trials website and official regulatory approval packages.

Q: Is Cartan only for long-term conditions?

Cartan is described in official documents for the management of chronic conditions, including hypertension (high blood pressure) and diabetic nephropathy (kidney disease). This reflects the indication for its use as part of a continuous, long-term therapy plan.

Q: Is it possible for Cartan to stop working after a while?

Regulatory evidence from long-term clinical trials tracked the sustained efficacy of the medicine over time. This evidence reflects the expected sustained efficacy of the medicine over time, and a general loss of efficacy is not commonly cited as an adverse event in the official labeling.

How should Cartan be stored and disposed of?

How to Store and Dispose of Cartan (Losartan Potassium)

Losartan potassium tablets must be stored according to official regulatory requirements to maintain product stability and safety.

Storage Requirements

Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), protecting the medication from freezing and excess heat.
Environmental Protection: Keep the product in the original, tightly closed container and protect it from excess moisture and light.
Child Safety: It is mandatory to store all medication out of the sight and reach of children in a safe, locked location.

Disposal Instructions

Official disposal guidelines recommend returning unused or expired tablets to a drug take-back program or mail-back service. The medication must not be flushed down a toilet or poured down a drain. If no take-back option is available, unused tablets should be mixed with an undesirable substance, placed in a sealed bag, and disposed of in the household trash.

Cartan